Researchers are re-evaluating how medications like Adderall and Ritalin aid children with attention deficit hyperactivity disorder (ADHD) in maintaining focus.
Recent findings from a study analyzing thousands of adolescent brain scans support previous indications that these stimulant drugs have minimal direct influence on brain networks responsible for attention management.
Rather, it seems the medications stimulate networks associated with alertness and the anticipation of pleasure, as detailed in a report published in the journal Cell.
“It appears to be a combination of arousal and reward—a sort of one-two punch—that effectively assists kids with ADHD in managing tasks when they take these medications,” explains Dr. Benjamin Kay, a pediatric neurologist at Washington University in St. Louis and the study’s lead author.
The insights, alongside smaller studies, point to a “mindset shift regarding the function of stimulants” according to neuroscientist Peter Manza from the University of Maryland, who was not part of the research.
This investigation leveraged data from the Adolescent Brain Cognitive Development Study, a federally funded initiative encompassing brain scans from nearly 12,000 children. Among these, about 4% were diagnosed with ADHD upon entering the study, with nearly half prescribed a stimulant.
Currently, around 3.5 million children in the U.S. are on ADHD medications, with this figure continuing to rise.
How medications affect brain networks
The brain scan data included a type of MRI assessing brain activity during rest. This enabled Kay and his team to pinpoint which brain areas became more active in response to the drugs.
Initially, Kay anticipated seeing heightened activity in regions responsible for attention control.
“What I actually observed was that those specific areas were the least affected,” he remarks.
Instead, the medications triggered regions that help maintain wakefulness and anticipate rewarding experiences.
This dual response appears to stem from stimulants like Ritalin and Adderall increasing levels of two distinct brain chemicals, notes Dr. Nico Dosenbach, the paper’s senior author and a professor at Washington University.
The first is norepinephrine, which primes both body and brain for activity.
The study indicated that this “fight or flight” reaction mitigates the typical cognitive decline linked to sleep deprivation—a significant issue for many adolescents, particularly those with ADHD.
The second chemical, dopamine, plays a crucial role in the brain’s reward circuitry. An uptick in dopamine could help children with ADHD feel more engaged even with mundane tasks, such as homework.
Dosenbach points out that the brain typically expects, “this is going to be dull and unengaging.” However, dopamine may enhance tolerance, making tasks feel slightly rewarding.
While it’s premature to draw definite conclusions, Manza concurs that stimulants positively influence brain processes that support ADHD children in completing assignments.
“Math problems aren’t typically exciting for them, but after a dose of Ritalin, they might find them a bit more engaging,” he notes, indicating they become more willing to stick with the task.
Considering brain scans before pharmaceuticals?
Kay believes the new study’s insights should not reduce clinicians’ trust in the efficacy of stimulants for treating ADHD. However, it does suggest the necessity of addressing factors like sleep deprivation before opting for medication.
“This paper holds personal significance for me because I frequently prescribe these medications,” Kay comments.
The results also indicate that brain scans might eventually help identify which children would benefit most from drug treatments, Manza adds.
“Stimulants aren’t universally effective, so refining our targeting is crucial,” he says.
In the future, MRI scans might even enhance ADHD diagnoses, something Manza highlights as needed in a time when an increasing number of children and young adults are being diagnosed and prescribed medications.
